ATLANTA–(BUSINESS WIRE)–Holzer & Holzer, LLC is investigating whether certain statements issued
by Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) complied
with federal securities laws. On October 9, 2018, the minutes from
Trevena’s April 28, 2016 meeting with the Food and Drug Administration
(“FDA”) were released, which disclosed that the FDA “did not agree” with
several aspects of Trevena’s Phase 3 study for Oliceridine. The price of
Trevena’s stock declined following the report.
If you purchased Trevena common stock and suffered a loss on that
investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com
or Marshall P. Dees, Esq. at firstname.lastname@example.org,
or by toll-free telephone at (888) 508-6832 to discuss your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its
practice to vigorous representation of shareholders and investors in
litigation nationwide, including shareholder class action and derivative
litigation. More information about the firm is available through its
and upon request from the firm. Holzer & Holzer, LLC has paid for the
dissemination of this promotional communication, and Corey D. Holzer is
the attorney responsible for its content.
Holzer & Holzer, LLC
Corey D. Holzer, Esq., 888-508-6832